Lorenzo Cani, Medical Doctor at University of Turin, shared a post on X:
“Finally out in The Lancet Haematology the EMN-20 trial. KRD with weekly K and MRD driven approach for K discontinuation led to a 60% MRD negativity rate at 2 yrs in NTE NDMM fit and intermediate-fit patients.”
Title: Carfilzomib–lenalidomide–dexamethasone versus lenalidomide–dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial
Authors: Sara Bringhen, Lorenzo Cani, Elisabetta Antonioli, Daniele Derudas, Francesca Fazio, Alessandra Larocca, Sonia Ronconi, Claudia Cellini, Antonietta Pia Falcone, Fabrizio Accardi, Anna Marina Liberati, Piero Galieni, Angelo Belotti, Anna Maria Cafro, Roberto Ria, Giulia Benevolo, Iolanda Donatella Vincelli, Donato Mannina, Flavia Lotti, Benedetto Bruno, Vincenzo Marasco, Rita Mazza, Patrizia Tosi, Elena Rivolti, Mario Boccadoro, Mattia D’Agostino
Read the Full Article.
